Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis
Open accessThe DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in western countries. Despite the high prevalence of NAFLD, the underlying biology of the disease progression is not clear, and there are no approved drugs to treat non-alcoholic steatohepatitis (NASH), the most advanced form of the disease. Thus, there is an urgent need for developing advanced in vitro human cellular systems to study disease mechanisms and drug responses. We attempted to create an organoid system genetically predisposed to NAFLD and to induce steatosis and fibrosis in it by adding free fatty acids. We used multilineage 3D spheroids composed by hepatocytes (HepG2) and hepatic stellate cells (LX-2) with a physiological ratio (24:1). HepG2 and LX-2 cells are homozygotes for the PNPLA3 I148M sequence variant, the strongest genetic determinant of NAFLD. We demonstrate that hepatic stellate cells facilitate the compactness of 3D spheroids. Then, we show that the spheroids develop accumulations of fat and collagen upon exposure to free fatty acids. Finally, this accumulation was rescued by incubating spheroids with liraglutide or elafibranor, drugs that are in clinical trials for the treatment of NASH. In conclusion, we have established a simple, easy to handle, in vitro model of genetically induced NAFLD consisting of multilineage 3D spheroids. This tool may be used to understand molecular mechanisms involved in the early stages of fibrogenesis induced by lipid accumulation. Moreover, it may be used to identify new compounds to treat NASH using high-throughput drug screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MASLD modeling using co-cultures aims to reproduce the tissue microenvironment of the liver, including intercellular interactions between hepatocytes and non-parenchymal cells (stellate, immune), which is a key factor in the progression from steatosis to steatohepatitis and fibrosis [132,133,134].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [132]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In more complex systems (3D cultures, co-cultures), lower FFA concentrations (10–500 μM) are required [131,132,133,134], which brings conditions closer to physiological ones and reduces the risk of non-specific cytotoxicity.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [132]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For genetic studies of PNPLA3-dependent mechanisms, HepG2 + LX-2 3D spheroids [132] utilizing endogenous PNPLA3 I148M homozygosity serve as a unique platform.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [132]
In the citing paper
“Co-culturing cells using conventional 2D methods or in 3D spheroids allows for functional characterisation of these interactions,14 but is hampered by the poor reproduction of the environment that drives NASH in vivo, with investigations often limited to 2 subpopulations rather than the multicellular environment.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 1×
“NAFLD encompasses a wide spectrum of pathologic conditions, including hepatic steatosis and non-alcoholic steatohepatitis (NASH), which can further progress to fibrosis, cirrhosis and hepatocellular carcinoma [2].”
BackgroundMechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · cited 2×
“We found an increase in collagen levels after fatty acids treatment and as expected after treatment with TGF-β [48–50] the most potent fibrogenic cytokine [20].”
BackgroundHepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 1×
“However, after liver injury HSCs transdifferentiate and start producing extracellular matrix (ECM) proteins [17,19,21,22].”
BackgroundThe third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817 · cited 1×
“For instance, 3D cell cultures represent more closely the heterogeneous cell–cell interactions and offer a more similar micro-environment to the in vivo situation with respect to cell shape, adhesion, behavior, topology, and morphology [14].”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · cited 1×
“Of note, clinical studies show how severe fibrosis is the best predictor of mortality in patients with NAFLD [16].”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942 · cited 1×
“TGF-β is critical for the activation of fibrogenic myofibroblasts, which in response to injury upregulate α-smooth muscle actin (α-SMA) and secrete extracellular matrix proteins, mostly collagen Type I [38,39].”
BackgroundFrom 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834 · cited 1×
“This need has led to generation of more complex 3D in vitro models that have generated great attention [13].”
Background
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“, 2020), or spheroids using cell lines (Pingitore et al., 2019) offers the prospect of dissecting these interactions and establishing a platform for highthroughput testing of candidate therapeutic agents.”
BackgroundLiver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Cherubini, A., Ostadreza, M., Jamialahmadi, O., Pelusi, S., Rrapaj, E., Casirati, E., Passignani, G., Norouziesfahani, M., Sinopoli, E., Baselli, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02553-8 · Cited by 136
“Finally, to test a causal role of ER-α-dependent induction of steatosis on fibrosis development, HepG2 cells were cocultured with human immortalized hepatic stellate cells (LX-2, homozygous for the p.I148M variant) to generate three-dimensional (3D) multilineage hepatic spheroids 45 .”
MethodSelf-citationTanaka, Y., Shimanaka, Y., Caddeo, A., Kubo, T., Mao, Y., Kubota, T., Kubota, N., Yamauchi, T., Mancina, R. M., Baselli, G., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320646 · Cited by 132
Self-citationLiver-on-a-Chip models of fatty liver disease
Hassan, S., Sebastian, S., Maharjan, S., Lesha, A., Carpenter, A., Liu, X., Xie, X., Livermore, C., Zhang, Y. S., & Zarrinpar, A. (2020) · Hepatology · doi:10.1002/hep.31106 · Cited by 127
“Hepatic spheroids recreate 3D liver tissues resembling native structure and function, including fat accumulation and collagen deposition.(5,6) However, they are typically static and limited in architecture and incorporation of multiple cell types.”
BackgroundIn Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
“A similar system proved relevant to investigate themost common genetic variant in NAFLD patients, PNPLA3 I148M (Pingitore et al., 2019), and study the mechanisms involved in the early stages of fibrogenesis induced by lipid accumulation.”
BackgroundInfluentialIn Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121
“hepatic steatosis can be induced by supplementing the culture medium with pathophysiological concentrations of FFA, carbohydrates and insulin [49,50].”
BackgroundUnderstanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
Shinn, J., Park, S., Lee, S., Park, N., Kim, S., Hwang, S., Moon, J. J., Kwon, Y., & Lee, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c06107 · Cited by 115
Animal and Organoid Models of Liver Fibrosis
Bao, Y., Wang, L., Pan, H., Zhang, T.-R., Chen, Y., Xu, S.-J., Mao, X., & Li, S.-W. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.666138 · Cited by 114
“In addition, these systems can be used to identify new compounds for treating NASH through high-throughput drug screening (Pingitore et al., 2019).”
BackgroundA comprehensive review on 3D tissue models: Biofabrication technologies and preclinical applications
Xie, R., Pal, V., Yu, Y., Lu, X., Gao, M., Liang, S., Huang, M., Peng, W., & Ozbolat, I. T. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122408 · Cited by 120
Organoids: a novel modality in disease modeling
Heydari, Z., Moeinvaziri, F., Agarwal, T., Pooyan, P., Shpichka, A. I., Maiti, T. K., Timashev, P. S., Baharvand, H., & Vosough, M. (2021) · Bio-Design and Manufacturing · doi:10.1007/s42242-021-00150-7 · Cited by 110
“A physiological phenotype was restored by incubating the organoids with anti-steatotic and anti-fibrotic drugs, including liraglutide and elafibranor [137].”
BackgroundModelling metabolic diseases and drug response using stem cells and organoids
Hu, W., & Lazar, M. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00733-z · Cited by 107
Berardo, C., Pasqua, L. G. D., Cagna, M., Richelmi, P., Vairetti, M., & Ferrigno, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249646 · Cited by 98
Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis
Hurrell, T., Kastrinou-Lampou, V., Fardellas, A., Hendriks, D. F. G., Nordling, Å., Johansson, I., Baze, A., Parmentier, C., Richert, L., & Ingelman-Sundberg, M. (2020) · Cells · doi:10.3390/cells9040964 · Cited by 82
“other systems having been applied to investigate NAFLD and fibrosis, which do not make use of primary human tissue to generate hetero-cellular models [46,47].”
Elbadawy, M., Yamanaka, M., Goto, Y., Hayashi, K., Tsunedomi, R., Hazama, S., Nagano, H., Yoshida, T., Shibutani, M., Ichikawa, R., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119823 · Cited by 78
Gori, M., Giannitelli, S. M., Torre, M., Mozetic, P., Abbruzzese, F., Trombetta, M., Traversa, E., Moroni, L., & Rainer, A. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001163 · Cited by 76
Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply
Du, K., Li, S., Li, C., Li, P., Miao, C., Luo, T., Qiu, B., & Ding, W. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.07.013 · Cited by 69
Novel patient-derived preclinical models of liver cancer
Bresnahan, E., Ramadori, P., Heikenwalder, M., Zender, L., & Lujambio, A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.028 · Cited by 67
Youhanna, S. C., Kemas, A. M., Preiss, L. C., Zhou, Y., Shen, J. X., Cakal, S. D., Paqualini, F. S., Goparaju, S. K., Shafagh, R. Z., Lind, J. U., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000238 · Cited by 67
3D human liver spheroids for translational pharmacology and toxicology
Ingelman‐Sundberg, M., & Lauschke, V. M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13587 · Cited by 62
Shao, W., Xu, H., Zeng, K., Ye, M., Pei, R., & Wang, K. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04139-2 · Cited by 63
Ströbel, S., Kostadinova, R., Fiaschetti-Egli, K., Rupp, J., Bieri, M., Pawlowska, A., Busler, D., Hofstetter, T., Sanchez, K., Grepper, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01951-7 · Cited by 56
“, HepG2 and LX2, to represent hepatocytes and stellate cells, respectively [55].”
BackgroundLiver-on-a-chip devices: the pros and cons of complexity
Dalsbecker, P., Adiels, C. B., & Goksör, M. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00346.2021 · Cited by 64
In Vitro Liver Toxicity Testing of Chemicals: A Pragmatic Approach
Tabernilla, A., Rodrigues, B. D. S., Pieters, A., Caufriez, A., Leroy, K., Campenhout, R. V., Cooreman, A., Gomes, A. R., Arnesdotter, E., Gijbels, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095038 · Cited by 61
Kostrzewski, T., Snow, S., Battle, A. L., Peel, S., Ahmad, Z., Basak, J., Surakala, M., Bornot, A., Lindgren, J., Ryaboshapkina, M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02616-x · Cited by 52
Self-citationFabrication of Cell Spheroids for 3D Cell Culture and Biomedical Applications
Park, S. Y., Hong, H. J., & Lee, H. J. (2022) · BioChip Journal · doi:10.1007/s13206-022-00086-9 · Cited by 54
“Reprinted with permission from [71] 1 3 disease (NAFLD) model to test liraglutide and elafibranor, which are currently being clinically tested for use against NAFLD [89].”
BackgroundChu, X., Wang, X., Feng, K., Bi, Y., Xin, Y., & Liu, S. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02483-z · Cited by 50
“The HepG2/LX-2 spheroids were generated as described by Pingitore et al. [25].”
PSD3 downregulation confers protection against fatty liver disease
Mancina, R. M., Sasidharan, K., Lindblom, A., Wei, Y., Ciociola, E., Jamialahmadi, O., Pingitore, P., Andréasson, A., Pellegrini, G., Baselli, G., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-021-00518-0 · Cited by 47
Self-citationSchwartz, B. E., Rajagopal, V., Smith, C., Cohick, E., Whissell, G., Gamboa, M., Pai, R., Sigova, A., Grossman, I., Bumcrot, D., et al. (2020) · Cells · doi:10.3390/cells9102247 · Cited by 42
“It has been previously shown that this system can reproduce the fat reduction and anti-fibrotic effects of elafibranor, a phase 3 PPARα/δ inhibitor being developed for NASH [17].”
BackgroundMethodSelf-citationThree-Dimensional Cell Co-Culture Liver Models and Their Applications in Pharmaceutical Research
Ma, Y., Hu, L., Tang, J., Guo, W., Feng, Y., Liu, Y., & Tang, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076248 · Cited by 46
“[69] generated mixed cell spheroids of HepG2 cells and immortalized hepatic stellate cells (LX‐2) at a 1:1 or a physiological ratio of 24:1 in ultra‐low attachment 96‐well plates, to construct a non‐alcoholic fatty liver‐like organ system.”
BackgroundMicrofluidic Liver-on-a-Chip for Preclinical Drug Discovery
Fu, J., Qiu, H., & Tan, C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041300 · Cited by 42
“The microporous array processed by the low-adhesion layer was used to improve the pooling of multiple spheroids [82,83], and successfully generated up to 100 spheroids (Figure 2D).”
Method3D culture models to study pathophysiology of steatotic liver disease
Caddeo, A. M., Maurotti, S., Kovooru, L., & Romeo, S. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117544 · Cited by 43
Self-citationLiver organoid culture methods
Hu, Y., Hu, X., Luo, J. C., Huang, J., Sun, Y., Li, H., Qiao, Y., Wu, H., Li, J., Zhou, L., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01136-x · Cited by 42
Gomaraschi, M., Fracanzani, A. L., Dongiovanni, P., Pavanello, C., Giorgio, E., Dalt, L. D., Norata, G. D., Calabresi, L., Consonni, D., Lombardi, R., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.158523 · Cited by 41
Mannaerts, I., Eysackers, N., van Os, E. A., Verhulst, S., Roosens, T., Smout, A., Hierlemann, A. R., Frey, O., Leite, S. B., & van Grunsven, L. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120335 · Cited by 36
Youhanna, S. C., Kemas, A. M., Wright, S. C., Zhong, Y., Klumpp, B., Klein, K., Motso, A., Michel, M., Ziegler, N., Shang, M.-M., et al. (2024) · Advanced Science · doi:10.1002/advs.202407572 · Cited by 40
Romualdo, G. R., da Silva, T. C., Landi, M. F. D. A., Morais, J. Á., Barbisan, L. F., Vinken, M., de Oliveira, C. P. M. S., & Cogliati, B. (2020) · Environmental Toxicology · doi:10.1002/tox.23021 · Cited by 34
“(FA) medium enrichment have been established and validated as useful translational tools for the investigation of predispositional and therapeutic factors for liver diseases.(19,20) Sorafenib, a multi-kinase inhibitor approved by the FDA for the”
BackgroundBergamot Polyphenol Extract Reduces Hepatocyte Neutral Fat by Increasing Beta-Oxidation
Mirarchi, A., Mare, R., Musolino, V., Nucera, S., Mollace, V., Pujia, A., Montalcini, T., Romeo, S., & Maurotti, S. (2022) · Nutrients · doi:10.3390/nu14163434 · Cited by 31
“The HepG2 + LX-2 spheroids were generated as previously described [14].”
MethodSelf-citationSun, B., Liang, Z., Wang, Y., Yu, Y., Zhou, X., Geng, X., & Li, B. (2024) · Toxicology · doi:10.1016/j.tox.2024.153829 · Cited by 30
Leslie, J., Krishnamurthy, K. A., Gopalsamy, I. K., Inácio, P., Huch, M., Gallage, S., Oakley, F., & Vacca, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01162-9 · Cited by 30
Development of 3D Hepatic Constructs Within Polysaccharide-Based Scaffolds with Tunable Properties
Labour, M.-N., Guilcher, C. L., Aid, R., Samad, N. E., Lanouar, S., Simón‐Yarza, T., & Letourneur, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103644 · Cited by 27
Experimental models of fatty liver diseases: Status and appraisal
Wang, H., Shen, H., Seo, W., & Hwang, S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000200 · Cited by 26
Gaining New Biological and Therapeutic Applications into the Liver with 3D In Vitro Liver Models
Lee, S. W., Jung, D. J., & Jeong, G. S. (2020) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-020-00245-9 · Cited by 26
Shi, B., Wang, W., Ye, M., Liang, M., Yu, Z., Zhang, Y., Liu, Z., Liang, X., Ao, J., Xu, F. L., et al. (2023) · Liver International · doi:10.1111/liv.15558 · Cited by 26
NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models
Fang, J., Celton‐Morizur, S., & Desdouets, C. (2023) · Cancers · doi:10.3390/cancers15143723 · Cited by 27
“Following exposure to FFA or cyclosporine A, cocultured spheroids displayed enhanced steatogenesis and collagen production, an upregulation of the genes associated with fibrosis progression, such as TIMP metallopeptidase inhibitor 1 (TIMP1) or actin alpha 2 (ACTA2), HSC activation, and the induction of pro-inflammator…”
BackgroundMethodCavalcante, L. N., Porto, J., Mazo, D. F. D. C., Longatto‐Filho, A., Stefano, J. T., Lyra, A. C., Carrilho, F. J., Reis, R. M., Alves, V. A. F., Sanyal, A. J., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100728 · Cited by 25
Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk
Martins, M. C., Dixon, E. D., Lupo, G., Claudel, T., Trauner, M., & Rombouts, K. (2024) · Liver International · doi:10.1111/liv.16117 · Cited by 27
“The impact of free fatty acid exposure was rescued by incubation with drugs such as liraglutide or elafibranor, but not by vitamin E or obeticholic acid [88].”
PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes
Karamfilova, V., Gateva, A., Assyov, Y. S., Alexiev, A., Savov, A. S., Yaneva, N., Ivanova, I. D., Ivanova-Boyanova, R., Ivanova, R., Vlahova, Z., et al. (2019) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-506 · Cited by 25
“Lipid deposition in the liver seems to be critical in the pathogenesis of NAFLD, so its regulatory processes need to be further elucidated [16, 17].”
BackgroundAdvancements in MAFLD Modeling with Human Cell and Organoid Models
Wang, S.-X., Yan, J.-S., & Chan, Y.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911850 · Cited by 22
Sasidharan, K., Caddeo, A. M., Jamialahmadi, O., Noto, F. R., Tomasi, M., Malvestiti, F., Ciociola, E., Tavaglione, F., Mancina, R. M., Cherubini, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101352 · Cited by 22
Self-citationTutty, M. A., Vella, G., & Prina‐Mello, A. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01170-1 · Cited by 21
Alshehade, S. A., Zarzour, R. H. A., Murugaiyah, V., Lim, S. Y. M., El-Refae, H. G., & Alshawsh, M. A. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.09.001 · Cited by 20
“ALF 031997.06) conjugated to a BSA ratio of 1:5 (Pingitore et al., 2019).”
InfluentialSani, F., Zomorrod, M. S., Azarpira, N., & Soleimani, M. (2023) · Stem Cells International · doi:10.1155/2023/8836452 · Cited by 21
“The next day, the mixture was resuspended at a ratio of 1 : 10 in the complete medium and changed every other day [28].”
RetractedWagner, C., Hois, V., Pajed, L., Pusch, L.-M., Wolinski, H., Trauner, M., Zimmermann, R., Taschler, U., & Lass, A. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158730 · Cited by 20
“Thus, we used the human HSC cellline LX-2 (homozygous for the I148M variant [21]), primary human HSCs (carrying WT PNPLA3 alleles), and for comparison primary murine HSCs for cell culture experiments.”
MethodANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization
Pennisi, G., Maurotti, S., Ciociola, E., Jamialahmadi, O., Bertolazzi, G., Mirarchi, A., Bergh, P., Scionti, F., Mancina, R. M., Spagnuolo, R., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319789 · Cited by 18
Self-citationEmerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
Yang, Y., Zhao, Y., Li, W., Wu, Y., Wang, X., Wang, Y., Liu, T.-M., Ye, T., Xie, Y., Cheng, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112311 · Cited by 17
Pelechá-Salvador, M., Villanueva-Bádenas, E., Timor-López, E., Donato, M. T., & Tolosa, L. (2021) · Antioxidants · doi:10.3390/antiox11010086 · Cited by 19
“Treatment with a mixture of NEFA brought about an increase in cytoplasmic lipids and a higher COL1A1 expression, and allowed the effects of anti-NASH drugs such as liraglutide or elafibranor to be studied [66].”
BackgroundMethodLiver organoids in domestic animals: an expected promise for metabolic studies
Baquerre, C., Montillet, G., & Pain, B. (2021) · Veterinary Research · doi:10.1186/s13567-021-00916-y · Cited by 16
Frandsen, H. S., Vej-Nielsen, J. M., Smith, L. E., Sun, L., Mikkelsen, K. L., Thulesen, A. P., Hagensen, C. E., Yang, F., & Rogowska-Wrzesińska, A. (2022) · Cells · doi:10.3390/cells11203216 · Cited by 18
“This lack of knowledge is why no FDA-approved drug is available for NAFLD [4].”
BackgroundFröhlich, J., Raffaele, M., Skálová, H., Leire, E., Pata, I., Pata, P., Gorbunova, V. A., & Vinciguerra, M. (2022) · GeroScience · doi:10.1007/s11357-022-00713-1 · Cited by 22
PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide
Chen, Y., Yan, X., Xu, X. L., Yuan, S., Xu, F. L., & Liang, H. (2020) · Endocrine · doi:10.1007/s12020-020-02470-7 · Cited by 16
Martín‐González, M. Z., Palacios, H. H., Rodriguez, M. A., Arola, L., Aragonès, G., & Muguerza, B. (2020) · Nutrients · doi:10.3390/nu12020408 · Cited by 16
“our results indicated that low doses of CLA have the ability to decrease the gene expression of Ccl2 in the liver as well as the levels of diglycerides, which have been reported as key markers of hepatic inflammation [60,61].”
ResultNiu, H., Zhang, L., Wang, B., Zhang, G., Liu, J., Wu, Z., Du, S., & Zeng, Z. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00511 · Cited by 17
“9 In addition, the 3D model system is more similar to in vivo conditions, which makes it a realistic system for in vitro translation studies.”
Kumari, D., Gautam, J., Sharma, V., Gupta, S. K., Sarkar, S., Jana, P., Singhal, V., Babele, P., Kamboj, P., Bajpai, S., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22051 · Cited by 29
“A three-dimensional spheroid model was established by co-culturing two cell lines, HepG2 (hepatocellular carcinoma) and LX2 (hepatic stellate cells), following established protocols [47,60,61].”
MethodSpheroMold: modernizing the hanging drop method for spheroid culture
Guimaraes, A. P. P., Calori, I. R., Bi, H., & Tedesco, A. C. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1397153 · Cited by 15
Cottier, K. E., Bhalerao, D., Lewis, C., Gaffney, J., & Heyward, S. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-42785-9 · Cited by 15
Progress, application and challenges of liver organoids
Sang, C., Lin, J., Ji, S., & Gao, Q. (2024) · Clinical Cancer Bulletin · doi:10.1007/s44272-024-00012-0 · Cited by 16
“Co-culturing these two cells in a medium containing fatty acids, palmitic acid, and oleic acid induces lipid accumulation and collagen secretion, while anti-steatotic and anti-fibrotic drugs alleviate these symptoms [75, 76].”
Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease
Park, Y., Thadasina, D., Bolujo, I., Isidan, A., Cross-Najafi, A. A., Lopez, K., Li, P., Dahlem, A. M., Kennedy, L. L., Sato, K., et al. (2022) · Seminars in Liver Disease · doi:10.1055/a-1934-5588 · Cited by 15
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Aasadollahei, N., Rezaei, N., Golroo, R., Agarwal, T., Vosough, M., & Piryaei, A. (2023) · EXCLI journal · doi:10.17179/excli2022-5892 · Cited by 17
USP10 Alleviates Palmitic Acid-induced Steatosis through Autophagy in HepG2 Cells
Xin, S., Pan, X., Xu, X., & Yan-yan, Y. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00060 · Cited by 19
Mansouri, M., Beemer, S., Kothapalli, C. R., Rhoades, T., Fodor, P. S., Das, D., & Leipzig, N. D. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c19962 · Cited by 14
Sánchez‐López, C. M., González, A., Ramírez‐Toledo, V., Bernal, D., & Marcilla, A. (2024) · International Journal for Parasitology · doi:10.1016/j.ijpara.2024.06.002 · Cited by 12
Stem Cell-based Therapy Strategy for Hepatic Fibrosis by Targeting Intrahepatic Cells
Deng, Y., Xia, B., Chen, Z., Wang, F., Lv, Y., & Chen, G. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10286-9 · Cited by 12
Controlled fabrication of functional liver spheroids with microfluidic flow cytometric printing
Zhang, P., Li, X., Chen, J. Y., & Abate, A. R. (2022) · Biofabrication · doi:10.1088/1758-5090/ac8622 · Cited by 12
“This can be attributed to the production of collagen by the HSCs, which makes the spheroids more compact [17].”
Wang, E. Y., Zhao, Y., Okhovatian, S., Smith, J. B., & Radisic, M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1005051 · Cited by 15
“Liver fibrosis Davidson et al. (2017) developed a micropatterned tri-culture (MPTC) platform that displayed early fibrosis-like hepatic dysfunctions associated with non-alcoholic steatohepatitis (NASH).”
BackgroundInfluentialHepatic Lipoprotein Metabolism: Current and Future In Vitro Cell-Based Systems
Kiss, I., Neuwert, N., Oberle, R., Hengstschläger, M., Osmanagic-Myers, S., & Stangl, H. (2025) · Biomolecules · doi:10.3390/biom15070956 · Cited by 11
“For instance, lipid and collagen accumulations in HepG2 and LX-2 (stellate cell) 3D spheroids was reversed by treatment with liraglutide or elafibranor, drugs currently under investigation for MASH in clinal trials [224].”
The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease
Kotlyarova, A., Iskrina, A., & Kotlyarov, S. (2026) · International journal of molecular sciences · doi:10.3390/ijms27083399 · Cited by 10
Mice Hepatic Organoids for Modeling Nonalcoholic Fatty Liver Disease and Drug Response
Zhou, Z., Zheng, X., Xie, M., Lin, Z., Du, F., Shi, X., & Li, R. (2024) · Stem Cells and Development · doi:10.1089/scd.2024.0067 · Cited by 11
Evaluating pulmonary toxicity of PFOS and its alternative OBS using spheroids of A549 cells
Yao, C.-R., Jiang, Y., Li, S., Lu, Z., Long, X.-B., Xin, N., Zhang, J., Ma, D.-D., Ying, G., & Shi, W. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.176895 · Cited by 10
Chen, J., Wang, P., Li, Z. B., Wu, J., Tang, F., Yang, N., Cen, B., Xie, C., Yang, Y., Yang, Z., et al. (2025) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2025.01.019 · Cited by 11
Youhanna, S., Taebnia, N., Liang, Y., Cheng, N., Wang, Y., Michel, M., & Lauschke, V. M. (2025) · Advanced Biology · doi:10.1002/adbi.202500337 · Cited by 9
The application of organoid models in research into metabolic diseases
Song, Y., Lu, S., Gao, F., Wei, T., & Ma, W. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15390 · Cited by 9
Karnawat, K., Parthasarathy, R., Sakhrie, M., Karthik, H., Krishna, K. V., & Balachander, G. M. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00738g · Cited by 8
Zaki, M. Y. W., Shetty, S., Wilkinson, A. L., Patten, D. A., Oakley, F., & Reeves, H. L. (2021) · Journal of Visualized Experiments · doi:10.3791/62868 · Cited by 8
Mazzocchi, A. R., Yoo, K. M., Nairon, K. G., Kirk, L. M., Rahbar, E., Söker, S., & Skardal, A. (2021) · Biomedical Materials · doi:10.1088/1748-605x/ac45eb · Cited by 8
3D hepatic mimics – the need for a multicentric approach
Sasikumar, S., Chameettachal, S., Kingshott, P., Cromer, B. A., & Pati, F. (2020) · Biomedical Materials · doi:10.1088/1748-605x/ab971c · Cited by 7
“Multilineage spheroids having HepG2 and LX2 (homozygous for PNPLA3 I148 M sequence variant) were used for the development of a NAFLD model (Pingitore et al 2019).”
MethodMorisseau, L., Pawlowski, V., Plaisance, V., Lucas, M., Legallais, C., Sakai, Y., Abderrahmani, A., Jellali, R., & Leclerc, É. (2025) · Biotechnology Progress · doi:10.1002/btpr.70075 · Cited by 6
“9 Among these, organ-on-chip platforms are strong candidates to complement or replace and traditional animal -based model.”
EASL position paper on preclinical models of steatotic liver disease
Gallage, S., Castro, R. E., Estall, J. L., Tabas, I. A., Anstee, Q. M., TINIAKOS, D. G., Szabó, G., Yu, J., Desdouets, C., Tacke, F., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.029 · Cited by 8
Decoding Liver Fibrosis: How Omics Technologies and Innovative Modeling Can Guide Precision Medicine
Codotto, G., Blarasin, B., Tiribelli, C., Bellarosa, C., & Licastro, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062658 · Cited by 6
“For this reason, we can conclude that this model is more constructed rather than naturally developed [31].”
Mochida, T., Miyoshi, M., Kakinuma, S., Shimizu, T., Tsuchiya, J., Watakabe, K., Inada, K., Kaneko, S., Kawai‐Kitahata, F., Murakawa, M., et al. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102642 · Cited by 6
Modeling Liver Development and Disease in a Dish
Iqbal, W., Wang, Y., Sun, P., & Zhou, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115921 · Cited by 6
“Liraglutide, elafibranor, or momelotinib are shown to rescue spheroids consisting of immortalized hepatic stellate cells (LX-2) and HepG2, that are homozygous for the PNPLA3 Ile148Met variant, from fat and collagen accumulation when exposed to FFA [142,143].”
BackgroundFeng, Q., Chen, H., Ren, M., Qiao, Y., Zou, J., Liang, X., Yu, L., Wu, Y., Chen, S., Sun, Y., et al. (2025) · Food Research International · doi:10.1016/j.foodres.2025.116976 · Cited by 7
Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach
Palasantzas, V. E. J. M., Struik, D., Bos, T., Withoff, S., Fu, J., Jonker, J. W., & Hoogerland, J. A. (2026) · Nutrients · doi:10.3390/nu18030388 · Cited by 6
“…[31] HepG2 cultured in DMEM (undefined glucose concentration) and stimulated with 0.5 mM FFA mix of oleic and palmitic acid (2:1) for 24 h Co-treatment for 24 h with 1, 2, 5 * and 10 mM butyrate Intracellular triglyceride concentration, Western blot [29] https://doi.org/10.3390/nu18030388”
InfluentialGalectin-3 inhibition ameliorates hepatic steatosis in a multilineage 3D spheroid model
Sedda, F., Caddeo, A. M., Sasidharan, K., Perra, G., Pal, R. R., Lai, N., Kowalik, M. A., & Perra, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326373 · Cited by 5
Self-citationPhysiomimetic In Vitro Human Models for Viral Infection in the Liver
McDuffie, D., Barr, D., Helm, M., Baumert, T. F., Agarwal, A., & Thomas, E. (2022) · Seminars in Liver Disease · doi:10.1055/a-1981-5944 · Cited by 5
Human liver organoid: modeling liver steatosis and beyond
Wei, J., Zhang, W., & Zhao, B. T. (2023) · Cell Regeneration · doi:10.1186/s13619-023-00161-y · Cited by 5
Tissue engineered models of adipose tissue dysfunction to investigate obesity-related comorbidities
Celebi, L. E., Ketchum, F., Bozkaya, D. N., & Zorlutuna, P. (2025) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ae1cfe · Cited by 4
“In a similar study, fat accumulation induced by FFA treatment was mitigated by incubating spheroids with liraglutide or elafibranor, two drugs currently being evaluated in clinical trials for the treatment of NASH and its associated fibrosis [153].”
Advanced three‐dimensional in vitro liver models to study the activity of anticancer drugs
Żuchowska, A., Frojdenfal, S., Trzaskowski, M., & Jastrzębska, E. (2024) · Biotechnology Journal · doi:10.1002/biot.202400159 · Cited by 4
“[24,37,38] They showed that the presence of stellate cells in the structure of the aggregate facilitates its compactness.”
BackgroundSharma, A., & Lee, H. (2024) · Antioxidants · doi:10.3390/antiox13111389 · Cited by 4
Metadata
- Authors
- Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S.
- Affiliations
- University of Gothenburg (SE)
- AstraZeneca (Sweden) (SE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Romeo, Stefano
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-04-02
- Volume
- 20
- Issue
- 7
- Pages
- 1629
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6480107
- OpenAlex
- W2935565749
- Cited by
- 152
- References
- 64
- Citations by year
- 2026: 28 · 2025: 22 · 2024: 19 · 2023: 23 · 2022: 22 · 2021: 16 · 2020: 19 · 2019: 2
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Vetenskapsrådet (2016-01527)
- Hjärt-Lungfonden (20120533)
- the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (SU 2018-04276)
- Novonordisk Foundation Grant for Excellence in Endocrinology (Excellence Project, 9321-430)
- Swedish Diabetes Foundation (DIA 2017-205)
- Research grant from AstraZeneca (Echo Project, 10033852)
- Wallenberg Academy Fellows from the Knut and Alice Wallenberg Foundation (KAW 2017.0203)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic steatosis, liver fibrosis, multicellular spheroids, organoids, PNPLA3 I148M, HepG2 cells, LX-2 cells, hepatic stellate cells, hepatocytes, free fatty acids, liraglutide, elafibranor, in vitro disease model, drug screening
- MeSH terms
- Liraglutide, Apolipoproteins B, Fatty Acids, Humans, Liver Cirrhosis, Models, Biological, Propionates, Spheroids, Cellular, Coculture Techniques, Cell Lineage, Collagen Type I, Chalcones, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.